^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GEN1047

    i
    Other names: GEN1047, DuoBody-CD3xB7H4
    Company:
    Genmab
    Drug class:
    CD3 agonist, B7-H4 inhibitor
    Related drugs:
    2ms
    GCT1047-01: GEN1047 for Solid Tumors - First in Human (FIH) Trial (clinicaltrials.gov)
    P1/2, N=500, Recruiting, Genmab | Trial completion date: Aug 2025 --> Jun 2026 | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    GEN1047
    over1year
    Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody-CD3xB7H4 in solid cancer models (SITC 2022)
    Currently, DuoBody-CD3xB7H4 is being investigated in a first-in-human clinical trial for the treatment of solid tumors known to express B7H4 ( NCT05180474 ), in which the MoA and PD, including biomarkers of response, will be clinically explored. Ethics Approval Animal experiments were performed according to the guidelines of the Institutional Animal Care and Use Committee (IACUC) and in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).
    PK/PD data • Preclinical
    |
    VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • GZMB (Granzyme B)
    |
    VTCN1 underexpression
    |
    GEN1047
    over2years
    Research Trial to Study Safety of GEN1047 (DuoBody®-CD3xB7H4) in Participants With Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=220, Recruiting, Genmab
    Clinical • New P1/2 trial
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    GEN1047